All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

ANCA-Associated Renal Vasculitis - An Update

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10173697" target="_blank" >RIV/00216208:11110/13:10173697 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064165:_____/13:10173697

  • Result on the web

    <a href="http://dx.doi.org/10.1159/000348634" target="_blank" >http://dx.doi.org/10.1159/000348634</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1159/000348634" target="_blank" >10.1159/000348634</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    ANCA-Associated Renal Vasculitis - An Update

  • Original language description

    ANCA-associated vasculitis (AAV) is a potentially life-threatening disease with frequent and often severe kidney involvement which may result in end-stage renal disease. Anti-PR3 and anti-MPO disease are genetically distinct diseases and may have a different pathogenesis. Recent discovery of new autoantibodies (anti-LAMP-2) and the role of complement activation in the pathogenesis of AAV could result in better monitoring of the activity of the disease and identification of new treatment targets. The outcome of patients with AAV has dramatically improved, but long-term mortality still remains relatively high partly due to effective but relatively toxic immunosuppressive treatment. Recent studies demonstrated that B-cell depletion with rituximab is comparable to cyclophosphamide as induction treatment in newly diagnosed AAV patients and better than cyclophosphamide in relapsing patients. Rituximab-based maintenance treatment is superior to standard treatment with azathioprine. The use of

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FE - Other fields of internal medicine

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Contributions to Nephrology

  • ISSN

    0302-5144

  • e-ISSN

  • Volume of the periodical

    181

  • Issue of the periodical within the volume

    2013

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    13

  • Pages from-to

    216-228

  • UT code for WoS article

    000322846600023

  • EID of the result in the Scopus database